Somaxon Pharmaceuticals, Inc. Release: SILENOR™ Data Presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies

SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that data from three Phase 3 clinical trials of the company’s product candidate SILENOR™ (doxepin HCl) for the treatment of insomnia were presented this week at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, Maryland.